- Funding Success: China-based Cispoly, a key player in gynecological tumor detection equipment, recently raised over 100 million yuan (US$14 million) in a successful series B funding round.
- Prominent Backing: The funding round was led by Prosperity7 Ventures, the diversified growth fund affiliated with Saudi Arabian energy giant Aramco, with participation from existing investor Sunland Fund, highlighting substantial support from reputable entities.
- Strategic Focus and Expansion: Established in 2020 by Liu Pei, Cispoly specializes in developing advanced methylation detection tools for early-stage gynecological tumors, and the raised funds will be strategically utilized for research and development, global expansion initiatives, and expediting product registrations.
China-based Cispoly startup announced it secured over 100 million yuan (US$14 million), led by Prosperity7 Ventures, the diversified growth fund of Saudi Arabian energy giant Aramco, according to a statement.
The Asian startup landscape is witnessing a surge in investments from the Middle East, with China-based Cispoly, a producer of gynecological tumor detection equipment, being a notable beneficiary.
In a recent series B funding round, the startup secured over 100 million yuan (US$14 million), led by Prosperity7 Ventures, the diversified growth fund of Saudi Arabian energy giant Aramco, and featuring participation from existing investor Sunland Fund.
Founded in 2020 by Liu Pei, Cispoly focuses on developing methylation detection tools for early-stage gynecological tumors, including cervical, ovarian, and endometrial cancers, along with products for women’s reproductive microbiota testing.
The funds will be allocated to R&D, global expansion, and expediting product registrations, with ongoing research projects in China and plans for expansion into Southeast Asia and Europe through medical institution partnerships.
Prosperity7 Ventures has a track record of investing in Chinese health tech startups, including backing Fourier Intelligence in previous funding rounds.
If you see something out of place or would like to contribute to this story, check out our Ethics and Policy section.
